Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEACAM5-MMAE protodrug
- Development stage
- Preclinical
- Lead developer
- Shasqi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
CEACAM5-MMAE protodrug is a preclinical antibody-drug conjugate (ADC) and protodrug being developed by Shasqi for the treatment of solid tumors. The therapeutic candidate targets Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5), a cell-surface glycoprotein that is highly expressed in various epithelial cancers, including colorectal, pancreatic, and non-small cell lung cancer (NSCLC). The drug is built upon Shasqi's proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform. Unlike traditional ADCs that rely on enzymatic cleavage or internalization for payload release, this "Click ADC" utilizes bioorthogonal click chemistry to trigger the release of the cytotoxic payload. The CEACAM5-MMAE protodrug consists of a CEACAM5-targeting antibody linked to a monomethyl auristatin E (MMAE) payload in an inactive protodrug form. The MMAE is selectively activated and released at the tumor site upon interaction with a chemical activator, thereby minimizing systemic exposure and potentially reducing the off-target toxicities typically associated with microtubule inhibitors.
- Other names
- ADC/protodrug (MMAE payload)
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on CEACAM5-MMAE protodrug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEACAM5-MMAE protodrug.